MS relapse

After receiving positive regulatory feedback from the U.S. Food and Drug Administration (FDA), Oculis is planning to expand clinical testing of its experimental therapy privosegtor as a potential treatment for acute relapses in people with multiple sclerosis (MS). Privosegtor is already being investigated as a treatment for…

A test using data from 18 blood biomarkers to track disease activity in multiple sclerosis (MS) was able to distinguish true MS relapses from symptom worsening unrelated to active inflammation with high accuracy in a small real-world study. The findings suggest Octave Bioscience’s Multiple Sclerosis Disease Activity (MSDA) test may…

Taking high-dose vitamin D supplements for more than a year can significantly cut relapse risks and ease disability for people with multiple sclerosis (MS), according to a comprehensive review of more than 30 clinical trials. These benefits were observed in patients who added the vitamin to their standard…

People who develop multiple sclerosis (MS) at age 50 or later are more likely to accumulate disability through mechanisms that are not directly linked to relapses or MRI activity than those with earlier-onset disease, according to an Italian registry study. “This suggests that the adverse prognostic effect of [late-onset…

Despite being converted into the same active ingredient, the newer multiple sclerosis (MS) drug Vumerity (diroximel fumarate) is associated with significantly lower relapse rates than the older medication Tecfidera (dimethyl fumarate), or its generics, in people with relapsing forms of MS. Those are the findings of a…

People with multiple sclerosis (MS) who were older than 60 had a low risk of disease flares whether they continued or stopped taking disease-modifying therapies (DMTs), according to a recent study. According to researchers, these data suggest that some older adults with MS may be able to consider…

The approved injection therapy Kesimpta (ofatumumab) is generally safe and helps most adults with relapsing forms of multiple sclerosis (MS) keep their disease stable over time with few or no relapses, a real-world study has found. The data show treatment is especially effective when started at a younger…

The U.S. Food and Drug Administration (FDA) has approved Scinopharm Taiwan’s glatiramer acetate injection, a generic of Copaxone, to treat multiple sclerosis (MS). Scinopharm is the first pharmaceutical company in Taiwan to win U.S. approval for glatiramer acetate, marking a significant milestone…

The National Institute for Health and Care Excellence (NICE) in England is recommending natalizumab — sold as Tysabri and Tyruko — as an option for certain people with hard-to-control multiple sclerosis (MS). NICE is responsible for deciding which medicines will be covered by the National Health Service…

This year has been a lot for me to deal with. It’s held more grief, trauma, and growing pains for me than any year before it. And it all started with a relapse of my relapsing-remitting multiple sclerosis (RRMS) that came after nearly nine years of remission following my…

Disability progression in relapsing forms of multiple sclerosis (MS) tends to follow one of four distinct patterns, according to long-term data from more than 5,000 people with relapsing-onset MS followed in an Italian registry. The study specifically found that disability progression could generally be categorized into four patterns: minimal-worsening,…

Fear of a sudden relapse or a gradual worsening of MS symptoms is common among people with multiple sclerosis (MS), according to a systematic review analyzing data from more than 3,000 people with MS. Those fears are not only widespread but also closely tied to poorer mental health, greater fatigue,…

Relapses in people with relapsing-remitting multiple sclerosis (MS) may be more common in spring and summer, coinciding with warmer temperatures, low humidity, and greater fluctuations in atmospheric pressure, according to a study from Poland. Stressful life events and infections were the most frequent potential relapse triggers, the study found.

There’s a kind of loneliness that comes from being almost understood — close enough for someone to recognize your outline, but not close enough to feel your weight. It’s a loneliness that doesn’t creep in all at once. It settles slowly, the way dust gathers on a shelf you thought…

I mentioned last week that I had been in the hospital recently with pneumonia and promised to elaborate. Without further ado or any gross details, I give you my recent tale of woe. As with many of my experiences, may it serve as a warning of what not to do.

The holidays have a way of turning up the volume on everything. The lights feel brighter, rooms feel busier, and even soft conversation seems amplified. Living with multiple sclerosis (MS) has taught me that this kind of noise isn’t just sound — it’s work. It’s one of the…

Simultaneously measuring levels of two blood proteins — glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) — may offer a clearer way to track both disease activity and disability progression in people with multiple sclerosis (MS), according to a new long-term study. Each…

Tyruko (natalizumab-sztn) is now commercially available in the U.S. as the first and only approved biosimilar to Tysabri for adults with relapsing forms of multiple sclerosis (MS). The therapy received approval from the U.S. Food and Drug Administration (FDA) in 2023 for all indications covered by the…

November feels like an inhale that hasn’t yet decided whether to sigh or sing. The mornings are quieter now, the air cooler, and for the first time in months, I also feel more peaceful. On the other side of a recent relapse with relapsing-remitting multiple sclerosis, facing…

Enrollment is complete for the randomized part of ENHANCE, a large clinical trial testing a new dosing schedule for Briumvi (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (MS), developer TG Therapeutics announced. This part of the Phase 3b ENHANCE study (NCT05877963) is specifically testing whether…

As I sit down at my desk to write this, tears are streaming down my face. My mind, soul, body, and heart are beyond wounded from living with relapsing-remitting multiple sclerosis (MS). This burden that I bear has taken a toll on me like nothing else. I ask myself,…

As a physician, I hang my hat on certainty, where a certain medical issue can be solved with a certain medication. But when it comes to real life, especially as a parent and a person living with multiple sclerosis (MS), I know there’s little certainty in everyday living. My…

During my hospital stay earlier this year, all I could think about was the relief that would come when I finally went home. I pictured sinking into my own bed, exhaling for the first time in weeks, catching up with all that had happened inside my body. I needed…

Living with multiple sclerosis (MS) often means constantly balancing what your body needs with what your life demands. Some days you’re managing symptoms like fatigue, while other days you’re trying to keep up with work, relationships, and other responsibilities that don’t pause for flare-ups or doctor appointments. Amid all…

Living with multiple sclerosis (MS) can sometimes feel like living with a trickster who changes the rules without warning just to amuse himself. One day, you are walking fine, and the next, your legs feel like they’ve been replaced with overcooked spaghetti. There’s fatigue, brain fog, and…

Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a low rate of disability progression in people with relapsing forms of multiple sclerosis (MS), with no new safety concerns reported. That’s according to new long-term data from the…

Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression for at least four years after starting on the approved therapy, according to new Phase 4 trial data. The results come from the CLARIFY-MS (NCT03369665) and MAGNIFY-MS (NCT03364036)…

Frexalimab, a therapy Sanofi is developing for multiple sclerosis (MS) patients, led to sustained reductions in disease activity in people with relapsing forms of MS over more than two years of treatment, while continuing to show a favorable safety profile. That’s according to new data from an…

Consuming large amounts of ultra-processed foods (UPF) — products high in additives, artificial ingredients, and extensive processing — is associated with increased disease activity in people with clinically isolated syndrome (CIS), which is the first presentation of multiple sclerosis (MS), a study has found. The analysis used a…

Life with multiple sclerosis (MS) is unpredictable, involving many unknowns. Symptoms can come and go, flare up without warning, and affect every aspect of our health, from movement to memory. Managing MS is already a full-time job, and the added weight of life’s uncertainties often makes it even more…